Secukinumab (Cosentyx):
Secukinumab is an Interleucin-17A (IL-17A) inhibitor, initially developed and approved for the treatment of moderate to severe plaque psoriasis. Later it was approved for psoriatic arthritis and ankylosing spondylitis.
- Key studies: The ongoing Sahara study, a phase 3 essay, is investigating the efficacy of Secukinumab in patients with HS. Preliminary results suggest a reduction in inflammatory nodules, although the complete results are pending. In an open study by Hofmann et al. In 2018, nine patients with serious HS were treated with Secukinumab, and 67% of patients showed a clinical improvement in HS symptoms.
- Conclusion: Although Secukinumab has demonstrated potential in the treatment of HS, particularly in the reduction of inflammatory nodules, additional investigation is necessary to confirm its effectiveness. The ongoing Sahara study can provide more definitive responses in the future.
- Anakinra (Kineret):
Anakinra is an interleucin-1 (IL-1) receptor antagonist, originally developed for the treatment of rheumatoid arthritis. It is also used for certain auto -inflammatory syndromes, such as inflammatory neonatal onset (Nomid) inflammatic disease.
- Key studies: Anakinra has demonstrated effectiveness to reduce inflammation and pain in patients with HS. In a randomized, double -blind study, placed with tznetakou et al. In 2016, 20 patients with moderate to severe HS were assigned randomly to receive Anakinra or placebo. The results showed that 78.9% of patients treated with Anakinra showed a significant reduction in disease activity, compared to 30% in the placebo group. In addition, a pilot study by Van der Zee et al. In 2010, six patients with serious treated with Anakinra (100 mg daily) involved. The six patients achieved partial or complete remission, with significant reductions in pain and inflammatory nodules.
Conclusion: Anakinra is a promising treatment for HS, particularly for those with serious or refractory disease. Its success rates vary from 79% to 100% in small studies, so it is a valuable option for patients who have not responded to other therapies.
Anakinra (Kineret):
Anakinra is an interleucin-1 (IL-1) receptor antagonist, originally developed for the treatment of rheumatoid arthritis. It is also used for certain auto -inflammatory syndromes, such as inflammatory neonatal onset (Nomid) inflammatic disease.
- Key studies: Anakinra has demonstrated effectiveness to reduce inflammation and pain in patients with HS. In a randomized, double -blind study, placed with tznetakou et al. In 2016, 20 patients with moderate to severe HS were assigned randomly to receive Anakinra or placebo. The results showed that 78.9% of patients treated with Anakinra showed a significant reduction in disease activity, compared to 30% in the placebo group. In addition, a pilot study by Van der Zee et al. In 2010, six patients with serious treated with Anakinra (100 mg daily) involved. The six patients achieved partial or complete remission, with significant reductions in pain and inflammatory nodules.
- Conclusion: Anakinra is a promising treatment for HS, particularly for those with serious or refractory disease. Its success rates vary from 79% to 100% in small studies, so it is a valuable option for patients who have not responded to other therapies.
Its biological therapiesCh As Adalimumab, Infiximab, Usstekinumab, Secukinumab and Anakinra represent a significant advance in the treatment of suppurative hydramentitis. These biological ones have shown various degrees of success in clinical trials, offering hope to patients fighting with this challenging condition. While these treatments are promising, the ongoing research is essential to completely establish its efficacy and safety in broader patients. As HS understanding continues to evolve, biological therapies can become an even more comprehensive part of the management of this complex condition.
